1. Home
  2. NGNE vs EBF Comparison

NGNE vs EBF Comparison

Compare NGNE & EBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$35.40

Market Cap

498.2M

Sector

Health Care

ML Signal

HOLD

Logo Ennis Inc.

EBF

Ennis Inc.

HOLD

Current Price

$21.45

Market Cap

519.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
EBF
Founded
2003
1909
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Office Equipment/Supplies/Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
498.2M
519.5M
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
NGNE
EBF
Price
$35.40
$21.45
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$63.57
N/A
AVG Volume (30 Days)
219.9K
160.6K
Earning Date
05-08-2026
04-20-2026
Dividend Yield
N/A
4.85%
EPS Growth
0.93
7.79
EPS
N/A
0.39
Revenue
N/A
N/A
Revenue This Year
N/A
$2.96
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.08
Revenue Growth
N/A
N/A
52 Week Low
$15.93
$16.30
52 Week High
$37.27
$22.36

Technical Indicators

Market Signals
Indicator
NGNE
EBF
Relative Strength Index (RSI) 68.81 56.43
Support Level $19.27 $19.92
Resistance Level $36.37 $22.36
Average True Range (ATR) 2.05 0.58
MACD 0.39 0.09
Stochastic Oscillator 95.22 75.39

Price Performance

Historical Comparison
NGNE
EBF

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About EBF Ennis Inc.

Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others. The company's single reportable segment : Print derives its operating revenues from the manufacturing of mostly custom or semi-custom printed products sold mostly to independent distributors in the United States.

Share on Social Networks: